Selected article for: "cardiac function and SARS cov"
Author: Raciti, Loredana; Calabrò, Rocco Salvatore
Title: Neurological complications of COVID-19: from pathophysiology to rehabilitation. An overview
  • Cord-id: ed083fyr
  • Document date: 2021_9_2
    • ID: ed083fyr
    Snippet: OBJECTIVE: To evaluate how the SARS-COV2 is able to affect the nervous system, the main neurological manifestation, and the treatment used, including neurorehabilitation. METHODS: Studies performed during the current year that fulfilled inclusion criteria were selected from PubMed, Scopus, Cochrane, and Web of Sciences databases. The search combined the terms “Covid 19,” “rehabilitation/treatment,” and “neurological complications.” RESULTS: The exact route by which SARS-CoV-2 can pen
    Document: OBJECTIVE: To evaluate how the SARS-COV2 is able to affect the nervous system, the main neurological manifestation, and the treatment used, including neurorehabilitation. METHODS: Studies performed during the current year that fulfilled inclusion criteria were selected from PubMed, Scopus, Cochrane, and Web of Sciences databases. The search combined the terms “Covid 19,” “rehabilitation/treatment,” and “neurological complications.” RESULTS: The exact route by which SARS-CoV-2 can penetrate the CNS is still unknown, although a possible retrograde transynaptic pathway from peripheral nerve endings, and/or through the olfactory bulb, have been suggested. An early management of COVID-19 by a multiprofessional team is fundamental to avoid long term sequaele. Rehabilitation is recommended to improve respiratory and cardiac function, as well as to avoid long term neurological complications. CONCLUSIONS: As no specific conclusions in term of prognosis and treatment could be done, research and consensus paper are needed to provide NeuroCovid patients with the best treatment options, including neurorehabilitation. (www.actabiomedica.it)

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute kidney injury: 1, 2, 3, 4
    • ace inhibitor and acute patient: 1
    • ace inhibitor and acute phase: 1
    • ace inhibitor and long period: 1
    • acute cardiac injury and long period: 1
    • acute cardiac injury and lopinavir ritonavir: 1, 2, 3, 4
    • acute cardiac injury and macrophage activation: 1
    • acute cardiac injury and macrophage activation syndrome: 1
    • acute cerebrovascular disease and long period: 1
    • acute cerebrovascular disease and los angeles: 1
    • acute episode and lung parenchyma: 1
    • acute illness and adjunct therapy: 1, 2
    • acute illness and lombardy region: 1
    • acute illness and long critical: 1, 2, 3
    • acute illness and long critical term: 1, 2, 3
    • acute illness and long period: 1, 2
    • acute illness and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
    • acute illness and lung parenchyma: 1, 2, 3